Get the Stockscreener App
1.42
0.00%
0.00
After Hours:
1.40
-0.02
-1.41%
Geron Corp stock is traded at $1.42, with a volume of 6.36M.
It is up +0.00% in the last 24 hours and down -16.47% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.42
Open:
$1.39
24h Volume:
6.36M
Relative Volume:
0.44
Market Cap:
$859.83M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-4.4375
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
+11.81%
1M Performance:
-16.47%
6M Performance:
-65.02%
1Y Performance:
-60.11%
1-Day Range:
$1.36
$1.44
1-Week Range:
$1.27
$1.47
52-Week Range:
$1.17
$5.34
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.42 | 859.83M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Canopy Growth Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
GERN INVESTOR NOTICE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - The Victoria Advocate
Investors who lost money on Geron Corporation(GERN) should contact Levi & Korsinsky about pending Class ActionGERN - PR Newswire
ROSEN, A LEADING NATIONAL FIRM, Encourages Geron Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action – GERN - GlobeNewswire Inc.
The Gross Law Firm Reminds Geron Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - PR Newswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Bancorp, Geron, enCore, and TFI and Encourages Investors to Contact the Firm - TradingView
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - StreetInsider
2025-04-20 | Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN | NDAQ:GERN | Press Release - Stockhouse
Geron Expands Team with 12 Strategic Hires, Grants $1.5M+ in Equity Awards Under Nasdaq Rule - Stock Titan
Is Geron Corp. (NASDAQ:GERN) the Most Promising Penny Stock According to Analysts? - Insider Monkey
Faruqi & Faruqi Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - StreetInsider
11 Most Promising Penny Stocks According to Analysts - Insider Monkey
Contact The Gross Law Firm by May 12, 2025 Deadline to Join Class Action Against Geron Corporation (GERN) - GlobeNewswire
Geron Shareholder Sues Executives Over Drug Launch Misrepresentations - USA Herald
Geron Shareholder Sues Execs Over Drug Launch Claims - Law360
Geron stock hits 52-week low at $1.19 amid sharp annual decline By Investing.com - Investing.com South Africa
Geron Brass Sued Over Cancer Drug Prospects After 32% Stock Drop - Bloomberg Law News
Geron stock hits 52-week low at $1.19 amid sharp annual decline - Investing.com Canada
Is Geron Corp. (NASDAQ:GERN) the Best Biotech Penny Stock to Buy According to Hedge Funds? - Insider Monkey
Geron Brass Sued Over Cancer Drug Prospects After Stock Drop (1) - Bloomberg Law News
13 Best Biotech Penny Stocks to Buy According to Hedge Funds - Insider Monkey
Class Action Filed Against Geron Corporation (GERN) Seeking Recovery for Investors – Contact The Gross Law Firm - GlobeNewswire
GERN Investors are Reminded of an Opportunity to Lead Geron Corp - GuruFocus
Geron (GERN) to Announce Q1 Financial Results - GuruFocus
Geron Corporation (GERN) Faces Significant Stock Decline Amidst Volatility - GuruFocus
2025-04-13 | Shareholders that Lost Money on Geron Corporation (GERN) Should Contact Levi & Korsinsky About Pending Class ActionGERN | NDAQ:GERN | Press Release - Stockhouse
Geron Corporation Class Action: Levi & Korsinsky Reminds Geron Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 12, 2025GERN - PR Newswire
Kirby McInerney LLP Urges Investors in Geron Corporation - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron Lawsuit – GERN - GlobeNewswire
GERN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Geron - GlobeNewswire
Geron Corp (GERN) Reports Q3 2023 Financial Results and Business Highlights - GuruFocus
Geron stock touches 52-week low at $1.27 amid market challenges - Investing.com
Geron's SWOT analysis: biotech firm's stock faces growth hurdles amid promising drug developments - Investing.com
Geron’s SWOT analysis: biotech firm’s stock faces growth hurdles amid promising drug developments - Investing.com Canada
Should You Invest in Geron Corporation (GERN)? - MSN
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of May 12, 2025 in Geron LawsuitGERN - PR Newswire
GERN Investors Have Opportunity to Lead Geron Corporation Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages Geron - GlobeNewswire
GERN INVESTOR DEADLINE: Geron Corporation Investors with Substan - GuruFocus
GERN INVESTOR DEADLINE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - The Victoria Advocate
GERN INVESTOR DEADLINE: Geron Corporation Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit – Company AnnouncementFT.com - Financial Times
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against XPLR, Geron, enCore, and Fluence and Encourages Investors to Contact the Firm - GlobeNewswire
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):